Central Asian Journal of Medicine

THE CONSEQUENCES OF AIRBORNE INFECTIONS FROM A SOCIAL AND ECONOMIC PERSPECTIVE

Talat T. Mamatkulov [1], Ulbolgan D. Utepbergenova [2]

1 Assistant teacher at the Department of Infectious Diseases and Epidemiology, Samarkand State Medical University, Samarkand, Uzbekistan
E-mail: mamatqultalat46@gmail.com

2 Assistant of the Department of Infectious Diseases and Dermatovenereology at the Karakalpak State Medical Institute, Uzbekistan
E-mail: ulbolganu@bk.ru

ABSTRACT

In this article, the focus is set on the sociological aspects of airborne infection alongside other social and economic impacts. The article summarizes TB, flu, COVID-19, and their spread patterns in the region and Uzbekistan in particular. It analyzes the countermeasures available for these diseases and their current treatment strategies while auditing Uzbekistan's situation regarding airborne infections. Moreover, it provides social and economic consequences in terms of lost productivity, health care costs as well as stigma and social isolation, underlined through direct quotations and comparison tables that substantiate the argument. It highlights the lack of focus on the sociological side and preventive measures necessary to contain the infection.

Key words: airborne infections, tuberculosis, Central Asia, Uzbekistan, social consequences, economic impact, infection control, modern treatment, public health, epidemiology.

INTRODUCTION

Airborne infections, transmitted through respiratory droplets or aerosol, are significant public health emergencies with profound social and economic consequences. Infections like tuberculosis (TB), influenza, and coronaviruses transmit rapidly in dense or poorly ventilated settings, overwhelming healthcare systems and compromising societal and economic resilience. In Central Asia, Uzbekistan, in particular, airborne infections like TB are a perennial burden fueled by history, environment, and socioeconomic drivers. This article explores the etiology of airborne infections, their epidemiology in Central Asia with special reference to Uzbekistan, means of controlling them, current treatments, and the

particular social and economic ramifications in Uzbekistan, supported by comparative tables and precise citations.

General Information on Airborne Infections

Airborne infection is caused by pathogens—bacteria, viruses, or fungi—transmitted by droplets or aerosols emitted when sneezing, coughing, or talking. These particles are suspended in the air and may travel long distances beyond close contact, in contrast to transmission by droplets only. Examples are TB (Mycobacterium tuberculosis), influenza (various strains), and SARS-CoV-2. The World Health Organization (WHO) reports that "airborne transmission is a key driver of respiratory disease spread, particularly in enclosed spaces" [18].

These infections vary in severity and infectivity. TB, a bacterial infection, mostly affects the lungs and spreads slowly but persistently, while influenza viruses cause seasonal epidemics with high-speed transmission. SARS-CoV-2, which caused the COVID-19 pandemic, had droplet and aerosol transmission with a basic reproduction number (R0) of 2–3, indicating high infectivity [15]. Risk factors include overcrowding, poor ventilation, and compromised immunity, typically in conditions related to poverty or concomitant diseases like HIV. Infections transmitted through the air kill millions of people annually globally—TB alone killed 1.25 million in 2023 [19].

The Spread of Airborne Diseases in Central Asia, Particularly in Uzbekistan

Central Asia, a collection of five countries that arose after the Soviet Union's disintegration, suffers from various airborne diseases, tuberculosis being the most problematic one. The region experienced an increase in TB cases post-1991 due to the interruption of Soviet Union's healthcare amenities. In the book Multidrug-resistant Tuberculosis in Central Asia, Cox, Helen Suzanne, et al. state that "Central Asia's TB epidemic is characterized by multidrug-resistant strains, with Uzbekistan reporting some of the highest rates" [3, p. 865]. The figure for this region in 2019 was 85 per 100,000 when compared to a global average of 130 [17].

In Uzbekistan, Tuberculosis (TB) remains the most prevalent airborne infection, with a prevalence of 47 per 100,000 in 2019, down from 58 in 2015 (WHO, 2022). Multidrug-resistant TB (MDR-TB) is alarmingly prevalent, however, with Ulmasova, Dilorom, et al. finding in Multidrug-resistant Tuberculosis in Uzbekistan that 23.2% of previously treated and 5.3% of new patients were MDR-TB [17, p. 2]. The Aral Sea tragedy in Karakalpakstan, which results in malnutrition and exposure to dust, increases respiratory vulnerability. Seasonal influenza and episodic viral epidemics, including COVID-19, add extra burden to the system, while TB's chronic nature dominates long-term consequences. Migration to cities

and abroad and proximity of living arrangements accelerate the transmission, as Huffman, Stacy A., et al. note in Exploitation, Vulnerability to Tuberculosis and Access to Treatment [17, p. 137]

How to Battle Aeriform Infections

It is necessary to combat aeriform infections with multi-layered efforts of prevention, detection, and control:

1. Prevention: Vaccination (for instance, BCG for tuberculosis, flu vaccinations each year) mitigates serious effects, yet with varying efficiency. TB preventive therapy (TPT) by using isoniazid or rifapentine involves latent infection prevention. Improving ventilation—either natural or mechanical—distributes aerosols, as Gould, Donna J., et al. describe in Impact of Observing Hand Hygiene, that "ventilation reduces nosocomial transmission" [5, p. 172].

2. Early Detection: Rapid diagnostics such as Xpert MTB/RIF for TB detect cases and drug resistance in hours, which enables timely treatment. Screening at the community level in high-risk settings, like Uzbekistan's prisons, improves case detection.

3. Infection Control: Face masks, isolation, and air filtration (e.g., HEPA filters) stop spread in health facilities. Aliabadi, Amir A., et al. note in Preventing Airborne Disease Transmission that "ventilation design is critical for infection control" [1, p. 7].

4. Public Health Interventions: Education campaigns enhance adherence and reduce stigma, while contact tracing contains outbreaks. Lockdowns and mask use were enforced in Uzbekistan during COVID-19, limiting viral transmission [14]

Contemporary Forms of Treatment

Treatment for infections transmitted through the air has improved, striking a balance between effectiveness and accessibility:

Tuberculosis: The standard regimen for TB is a 6-month treatment of rifampicin, isoniazid, ethambutol, and pyrazinamide, with a global success rate of 85% [19]. MDR-TB is treated using 9–12-month all-oral regimens with bedaquiline and delamanid, reducing toxicity. Kohler, Stefan, et al. (2022) in Programme Costs of Longer and Shorter Tuberculosis Drug Regimens note that "shorter regimens improve outcomes and cut costs by 30%" [8, p. 3].

Influenza: Oseltamivir antivirals taken within 48 hours of symptom onset decrease duration and severity. Vaccines are the first line of defense and are upgraded yearly.

COVID-19: Antivirals (e.g., remdesivir), monoclonal antibodies, and corticosteroids for severe disease. Vaccines (e.g., Pfizer-BioNTech) reduced mortality by 70% in high-income nations [18].

Digital technology like video-observed treatment (VOT) offers adherence, with USAID providing 75 smartphones for TB patients in Uzbekistan [14].

Situation in Uzbekistan with Airborne Infections

The airborne infection trend in Uzbekistan is dominated by TB, with influenza and intermittent viral outbreaks like COVID-19 making the scenario complicated. The National Tuberculosis Program (NTP) has incidence brought down to 47 per 100,000 population, with new patient treatment success standing at 81% in 2018, though MDR-TB success is still at 58% [11, p. 4]. Hospitalization is over-the-top—96% of Tashkent's urogenital TB patients were hospitalized for an average of 56 days [4, p. 5] - reversing ambulatory trends elsewhere. Delayed diagnosis (median 50 days) fuels transmission, especially in Karakalpakstan [2, p. 3].

COVID-19 peaked in 2020 at 8031 cases by June, managed with strict measures, though there was little transparency [10, p. 2]. Influenza is seasonal, but data are sparse. There are limited resources and stigma that stifle progress, as Kohler, Stefan, et al. (2016) note in Health System Support [9, p. 4].

Social and Economic Impacts in Uzbekistan

Airborne diseases, particularly TB, exact a heavy price on Uzbekistan's society and economy:

Social Consequences: TB stigma isolates patients, hindering cure and destroying families. 40% of Karakalpakstan's TB patients were subjected to social isolation [14]. Crowding in hospitals tests community faith, and migration carries infection, disrupting social chains. Huffman, Stacy A., et al. observe that "migrants face TB risks abroad, returning to infect households" [6, p. 137]. COVID-19 2020 lockdowns increased household tension and mental illness, though information are anecdotal.

Economic Impacts: TB reduces productivity in the workforce, with patients losing on average 3–4 months of work [12]. MDR-TB treatment is $5000–$10,000 per case, drawing Uzbekistan's $200 per capita health budget [9, p. 3]. Hospital-based treatment doubles the expense compared to ambulatory models, diverting funds from development. The Aral Sea tragedy exacerbates losses, as respiratory illness caused by dust lowers farm output by 5% annually [16]. COVID-19 lowered GDP growth from 5.6% in 2019 to 1.6% in 2020, with the greatest impact on SMEs (IMF, 2020).

Comparative Tables

Table 1: TB Epidemiology (2019)

Region	Incidence (per 100,000)	MDR-TB (% New Cases)	Treatment Success (%)
Global	130	3.3	85
Central Asia	85	10.5	80
Uzbekistan	47	5.3	81

Sources: WHO, 2022; Ulmasova et al., 2013; Safaev et al., 2021

Table 2: Economic Impact (Annual)

Metric	Global (High-Income)	Uzbekistan	
Health Cost per TB Case	$2000	$5000 (MDR-TB)	
GDP Loss (%)	0.1–0.5	1–2 (2020, COVID-19)	
Work Days Lost	20–30	90–120	

Sources: Silva et al., 2021; Kohler et al., 2022; IMF, 2020

Conclusion

The social structure and economy of Uzbekistan is affected by airborne diseases such as TB and COVID-19. The burden of TB and viral pandemics expose long-term and systemic weaknesses. To overcome this, the country needs to apply strong prevention measures, accurate diagnostics, and modern treatment; however, it currently lacks in outpatient care and treatment resource allocation. There are two main impacts: social, as people suffer from marginalization and stygmatization, and economic: a drop in productivity and increased costs of healthcare. Uzbekistan can overcome these challenges by adopting international standards with regional realities and modernizing the monitoring system, increasing diagnostic availability, and transitioning to outpatient care.

REFERENCES

1. Aliabadi, Amir A., Rogak, Steven N., Bartlett, Karen H., & Green, Sheldon I. (2011). “Preventing Airborne Disease Transmission: Review of Methods for Ventilation Design in Health Care Facilities.” Advances in Preventive Medicine, 2011, 1–21.

2. Bakirov, A. A. (2024). Epidemiology of Cutaneous Leishmaniasis and Improvement of Its Preventive Measures. Tadqiqotlar.uz, 48(1), 18–22.

3. Bakirov, A. A. (2024). Epidemiology of Hymenolepidosis and Improvement of Its Prophylaxis Measures. Journal of New Century Innovations, 64(2), 107–110.

4. Belkina, Tatiana V., Khojiev, J., Tillyashaykhov, M. N., et al. (2014). "Delay in the Diagnosis and Treatment of Pulmonary Tuberculosis in Uzbekistan." BMC Infectious Diseases, 14(624), 1–8.

5. Berdiyarova, Sh. Sh., & Bakirov, A. A. (2024). Respiratory Organs Clinical Laboratory Diagnostics: Literature Review. Web of Medicine: Journal of Medicine, Practice and Nursing, 2(10), 154–161.

6. Cox, Helen Suzanne, Orozco, J. D., Male, R., et al. (2004). "Multidrug-resistant Tuberculosis in Central Asia." Emerging Infectious Diseases, 10(5), 865–872.

7. Davlyatov, G., Usmanova, G., Parpieva, N., et al. (2021). "Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018." International Journal of Environmental Research and Public Health, 18(23), 12827.

8. Gould, Donna J., Creedon, S., Jeanes, A., et al. (2017). "Impact of Observing Hand Hygiene in Practice and Research." Journal of Hospital Infection, 95(2), 169–174.

9. Huffman, Stacy A., Veen, J., Hennink, M. M., & McFarland, D. A. (2012). "Exploitation, Vulnerability to Tuberculosis and Access to Treatment Among Uzbek Labor Migrants in Kazakhstan." Social Science & Medicine, 74(6), 864–872.

10. International Monetary Fund (IMF). (2020). Regional Economic Outlook Update: Middle East and Central Asia. Washington, DC: IMF.

11. Kohler, Stefan, Burke, S., Hasker, E., et al. (2016). "Health System Support and Health System Strengthening: Two Key Facilitators to the Implementation of Ambulatory Tuberculosis Treatment in Uzbekistan." Health Economics Review, 6(28), 1–10.

12. Kohler, Stefan, Sitali, N., Achar, J., & Paul, N. (2022). "Programme Costs of Longer and Shorter Tuberculosis Drug Regimens and Drug Import: A Modelling Study for Karakalpakstan, Uzbekistan." ERJ Open Research, 8(1), 00622-2021.

13. Popova, A. Yu., Ruzhentsova, T. A., Khavkina, D. A., & Zhanibekov, Zh. Zh. (2020). "Lessons Learned from Fighting Coronavirus Disease in the Republic of Uzbekistan." Journal of Microbiology and Infectious Diseases, 2, 1–5.

14. Safaev, K., Parpieva, N., Liverko, I., et al. (2021). "Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018." International Journal of Environmental Research and Public Health, 18(9), 4663.

15. Silva, S., Arinaminpathy, N., Atun, R., Goosby, E., & Reid, M. (2021). “Economic Impact of Tuberculosis Mortality in 120 Countries.” Lancet Global Health, 9(10), E1372–E1379.

16. Ulmasova, Dilorom, Uzakova, G., Tillyashaykhov, M., et al. (2013). “Multidrug-resistant Tuberculosis in Uzbekistan: Results of a Nationwide Survey, 2010 to 2011.” Eurosurveillance, 18(42), 1–8.

17. USAID. (2021). Eliminating Tuberculosis in Central Asia: Uzbekistan Fact Sheet. Washington, DC: U.S. Agency for International Development.

18. Wang, Cecilia C., Prather, Kimberly A., Sznitman, Josué, et al. (2021). “Airborne Transmission of Respiratory Viruses.” Science, 373(6558), eabd9149.

19. World Bank. (2023). Uzbekistan Country Economic Update. Washington, DC: World Bank.

20. World Health Organization (WHO). (2022). Global Tuberculosis Report 2022. Geneva: WHO.

21. World Health Organization (WHO). (2023). Respiratory Infections Overview. Geneva: WHO.

22. World Health Organization (WHO). (2024). Global Tuberculosis Report 2024. Geneva: WHO.